|
Malignant neoplasm of breast
|
0.560 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Hypertensive disease
|
0.020 |
Biomarker
|
group |
BEFREE |
<b>NEW & NOTEWORTHY</b> Angiotensin II (ANG II)-induced hypertension is dependent on the endosomal Toll-like receptor 3 (TLR3)-Toll-interleukin receptor domain-containing adaptor protein-inducing interferon-β (TRIF) pathway of the innate immune system but not on cell membrane localized TLR4.
|
30793936 |
2019 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
36 patients diagnose with RRMS treated with Interferon β-1b (IFNβ-1b) were enrolled in a double bind, randomized, placebo controlled trial.
|
30595364 |
2018 |
|
Nasal Polyps
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
4E-BP1 expression was decreased, whereas IFN regulatory factor-7 and IFN-β expression was increased, in eosinophilic CRSwNP.
|
22071331 |
2012 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
95 patients with relapsing-remitting MS treated with IFNβ-1b (mean follow-up 7.44 years) were studied.
|
21325856 |
2011 |
|
Hepatitis A
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Hepatitis A virus (HAV) antagonizes the innate immune response by inhibition of double-stranded RNA (dsRNA)-induced beta interferon (IFN-beta) gene expression.
|
16103148 |
2005 |
|
Virus Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Virus Infection Induces NF-kappaB-dependent interchromosomal associations mediating monoallelic IFN-beta gene expression.
|
18614013 |
2008 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
HCV replication directly induces IFNbeta, which then activates ISGs.
|
19688046 |
2009 |
|
Kaposi Sarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter.
|
20048166 |
2010 |
|
Leishmaniasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Leishmania infection increased the expression of PKR and IFN-β on induction of PKR-promoter activity.
|
21846836 |
2011 |
|
Rhinovirus infection
|
0.090 |
Biomarker
|
disease |
BEFREE |
Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients.
|
22657407 |
2012 |
|
Influenza
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Influenza virus infected cells treated with representative HuScFv (clone 10) had up-expression of IRF3 and IFN-β genes by 14.75 and 4.95-fold, respectively, in comparison with the controls, indicating that the antibodies could restore the host innate immune response.
|
23928258 |
2013 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multiple sclerosis (MS), an autoimmune inflammatory/neurodegenerative disease of the CNS, requires long-term medication with either specific disease-modifying therapy (DMT) - IFN-β or glatiramer acetate (GA) - which remain the only first-line DMTs in all countries.
|
24798724 |
2014 |
|
Schizophrenia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Schizophrenia subjects had markedly higher mRNA levels for interleukin 6 (IL-6) (+379%) and interferon-β (+29%), which induce IFITM expression; lower mRNA levels for Schnurri-2 (-10%), a transcriptional inhibitor that lowers IFITM expression; and higher mRNA levels for nuclear factor-κB (+86%), a critical transcription factor that mediates cytokine regulation of immune-related gene expression.
|
26133963 |
2015 |
|
Zika Virus Infection
|
0.030 |
Biomarker
|
disease |
BEFREE |
ZIKV infection of the placenta increases production of IFNβ and expression of IFN-stimulated genes 48 h after infection.
|
28220786 |
2017 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multiple sclerosis (MS) patients treated with interferon beta (IFNβ) are at risk of a declining response to treatment because of the production of IFNβ-neutralizing antibodies (NAbs).
|
28293479 |
2017 |
|
Influenza A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Influenza A virus non-structural protein 1 (NS1) antagonizes interferon response through diverse strategies, particularly by inhibiting the activation of interferon regulatory factor 3 (IRF3) and IFN-β transcription.
|
28717359 |
2017 |
|
Influenza A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Influenza A Virus PA Antagonizes Interferon-β by Interacting with Interferon Regulatory Factor 3.
|
28955326 |
2017 |
|
Japanese Encephalitis
|
0.060 |
Biomarker
|
disease |
BEFREE |
Japanese Encephalitis Virus NS1' Protein Antagonizes Interferon Beta Production.
|
30542978 |
2018 |
|
ENCEPHALITIS/ENCEPHALOPATHY, MILD, WITH REVERSIBLE MYELIN VACUOLIZATION
|
0.010 |
Biomarker
|
disease |
BEFREE |
MERS-CoV also effectively suppressed the antiviral interferon beta (IFNβ) response in human cells, unlike in bat cells.
|
30781790 |
2019 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Melanoma differentiation associated gene-7 (mda-7) selectively promotes these effects in cancer cells. mda-7 was identified more than two decades ago by subtraction hybridization showing elevated expression during induction of terminal differentiation of metastatic melanoma cells following treatment with recombinant fibroblast interferon and mezerein (a PKC activating agent).
|
31356866 |
2019 |
|
Middle East Respiratory Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design.
|
31452044 |
2019 |
|
Subacute Sclerosing Panencephalitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subacute sclerosing panencephalitis in a brother and sister. Therapeutic trial of fibroblast interferon.
|
6178588 |
1982 |
|
Malignant Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma.
|
10982152 |
2000 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interferon-beta (IFNbeta) is an effective treatment that lessens the frequency and severity of exacerbations in relapsing-remitting multiple sclerosis (RRMS).
|
11054484 |
2000 |